Finland· FI-REL-REL60933
Aumseqa
A aumolertinib product containing aumolertinib mesilate, registered in Finland by SFL Pharmaceuticals Deutschland GmbH. The same ATC class is registered in 8 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Aumolertinib is registered in 8 of 19 countries.
Countries holding a registration under ATC L01EB11 (aumolertinib), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 5 of them publish a price we can compare per daily dose
Aumolertinib · ATC L01EB11
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
Fimea (Finland)- Active substance
- Aumolertinib mesilate
- Manufacturer
- SFL Pharmaceuticals Deutschland GmbH
- Country
- Finland (FI)
- ATC code
- L01EB11
- ATC class
- Aumolertinib
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aumolertinib in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAumseqa 55 mgSfl Pharmaceuticals Deutschland
- CzechiaAUMSEQASFL Pharmaceuticals Deutschland GmbH, Lörrach
- IrelandAumseqa 55 mg film-coated tabletsSFL Pharmaceuticals Deutschland GmbH
- IcelandAumseqaSFL Pharmaceuticals Deutschland GmbH
- NetherlandsAumseqa 55 mg filmomhulde tabletSFL Pharmaceuticals Deutschland GmbH
- PolandAumseqaSFL Pharmaceuticals Deutschland GmbH
- SwedenAumseqa 55 mg Filmdragerad tablettSFL Pharmaceuticals Deutschland GmbH
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/52b754c4-5dff-43df-b202-932891979b20 GET /v1/drugs/52b754c4-5dff-43df-b202-932891979b20?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "tabletti, kalvopäällysteinen",
"route": "Suun kautta",
"ddd_unit": null,
"strength": "55 mg",
"atc_label": "aumolertinibi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/25/2006/001",
"fimea_rel_id": "REL60933",
"authorised_at": "2026-02-12"
}See everything about aumolertinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.